CCN2 and pancreatic neoplasm: Other studies have found that N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide, another preferential inhibitor of COX-2 over COX-1, reduced the human pancreatic cancer cell number through inhibiting the expressions of VEGF and CTGF (38).